{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:45:48Z","timestamp":1789659948719,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073377"],"award-info":[{"award-number":["82073377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772587"],"award-info":[{"award-number":["81772587"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003268"],"award-info":[{"award-number":["82003268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073396"],"award-info":[{"award-number":["82073396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872201"],"award-info":[{"award-number":["81872201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030310260"],"award-info":[{"award-number":["2018A030310260"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A0303130243"],"award-info":[{"award-number":["2018A0303130243"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515011464"],"award-info":[{"award-number":["2020A1515011464"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017B020227001"],"award-info":[{"award-number":["2017B020227001"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-JS2019-046"],"award-info":[{"award-number":["Y-JS2019-046"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced nasopharyngeal carcinoma (NPC) has a poor prognosis, with an unfavorable response to palliative chemotherapy. Unfortunately, there are few effective therapeutic regimens. Therefore, we require novel treatment strategies with enhanced efficacy. The present study aimed to investigate the antitumor efficacy of APG-1252-M1, a dual inhibitor of BCL-2\/BCL-XL, as a single agent and combined with gemcitabine. We applied various apoptotic assays and used subcutaneous transplanted NPC model to assess the in vitro and in vivo antitumor activity. Moreover, phospho-tyrosine kinase array was used to investigate the combined therapy\u2019s potential synergistic mechanism. In addition, further validation was performed using immunohistochemistry and western blotting. In vitro, we observed that APG-1252-M1 had moderate antitumor activity toward NPC cells; however, it markedly improved gemcitabine\u2019s ability to promote NPC cell apoptosis and suppress invasion, migration, and proliferation. Specifically, APG-1252 plus gemcitabine exhibited even remarkable antitumor activity in vivo. Mechanistically, the drug combination synergistically suppressed NPC by activating caspase-dependent pathways, blocking the phospho (p)-JAK-2\/STAT3\/MCL-1 signaling pathway, and inhibiting epithelial-mesenchymal transition. In conclusion, the results indicated that the combination of APG-1252 and gemcitabine has synergistic anticancer activities against NPC, providing a promising treatment modality for patients with NPC.<\/jats:p>","DOI":"10.1038\/s41419-021-04042-7","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T07:02:58Z","timestamp":1628146978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2\/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2\/STAT3\/MCL-1 signaling pathway"],"prefix":"10.1038","volume":"12","author":[{"given":"Fan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-9436","authenticated-orcid":false,"given":"Fei-Teng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miao-Zhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Mei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Fei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"4042_CR1","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.30198","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122:3307\u201315.","journal-title":"Cancer"},{"key":"4042_CR2","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","volume":"31","author":"LQ Tang","year":"2013","unstructured":"Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31:2861\u20139.","journal-title":"J Clin Oncol"},{"key":"4042_CR3","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(05)66698-6","volume":"365","author":"WI Wei","year":"2005","unstructured":"Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041\u201354.","journal-title":"Lancet"},{"key":"4042_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/annonc\/mdf179","volume":"13","author":"AT Chan","year":"2002","unstructured":"Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002;13:1007\u201315.","journal-title":"Ann Oncol"},{"key":"4042_CR5","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.ijrobp.2007.04.085","volume":"69","author":"B O\u2019Sullivan","year":"2007","unstructured":"O\u2019Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:S118\u2013121.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4042_CR6","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543\u201351.","journal-title":"J Clin Oncol"},{"key":"4042_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","volume":"33","author":"ML Telli","year":"2015","unstructured":"Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33:1895\u2013901.","journal-title":"J Clin Oncol"},{"key":"4042_CR8","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883\u201392.","journal-title":"Lancet"},{"key":"4042_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/annonc\/mdf002","volume":"13","author":"KF Foo","year":"2002","unstructured":"Foo KF, Tan EH, Leong SS, Wee JT, Tan T, Fong KW, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002;13:150\u20136.","journal-title":"Ann Oncol"},{"key":"4042_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","volume":"13","author":"RK Ngan","year":"2002","unstructured":"Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252\u20138.","journal-title":"Ann Oncol"},{"key":"4042_CR11","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1002\/cncr.30781","volume":"123","author":"SM Ali","year":"2017","unstructured":"Ali SM, Yao M, Yao J, Wang J, Cheng Y, Schrock AB, et al. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer. 2017;123:3628\u201337.","journal-title":"Cancer"},{"key":"4042_CR12","first-page":"7799","volume":"15","author":"HJ Zhang","year":"2018","unstructured":"Zhang HJ, Yuan GL, Liang QL, Peng XX, Cheng SA, Jiang L. Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma. Oncol Lett. 2018;15:7799\u2013805.","journal-title":"Oncol Lett"},{"key":"4042_CR13","doi-asserted-by":"publisher","first-page":"e1008223","DOI":"10.1371\/journal.ppat.1008223","volume":"16","author":"S Zhu","year":"2020","unstructured":"Zhu S, Chen J, Xiong Y, Kamara S, Gu M, Tang W, et al. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma. PLoS Pathog. 2020;16:e1008223.","journal-title":"PLoS Pathog"},{"key":"4042_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, nccn clinical practice guidelines in oncology. J Natl Compr Cancer NetW. 2020;18:873\u201398.","journal-title":"J Natl Compr Cancer NetW"},{"key":"4042_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"4042_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/bjc.1995.338","volume":"72","author":"P Hellemans","year":"1995","unstructured":"Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995;72:354\u201360.","journal-title":"Br J Cancer"},{"key":"4042_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/00005537-200204000-00009","volume":"112","author":"DK Trask","year":"2002","unstructured":"Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope. 2002;112:638\u201344.","journal-title":"Laryngoscope"},{"key":"4042_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4042_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","volume":"89","author":"WA Siddiqui","year":"2015","unstructured":"Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol. 2015;89:289\u2013317.","journal-title":"Arch Toxicol"},{"key":"4042_CR20","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1535-7163.MCT-16-0031","volume":"15","author":"RyanS Soderquist","year":"2016","unstructured":"Soderquist RyanS, Eastman A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Therapeutics. 2016;15:2011\u20137.","journal-title":"Mol Cancer Therapeutics"},{"key":"4042_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"4042_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbcan.2017.06.004","volume":"1868","author":"G Radha","year":"2017","unstructured":"Radha G, Raghavan SC. BCL2: A promising cancer therapeutic target. Biochim. Biophys. Acta Rev Cancer. 2017;1868:309\u201314.","journal-title":"Biochim. Biophys. Acta Rev Cancer"},{"key":"4042_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0959-8049(14)70464-2","volume":"50","author":"L Bai","year":"2014","unstructured":"Bai L, Chen J, Liu L, McEachern D, Aguilar A, Zhou H, et al. 338 BM-1252 (APG-1252): a potent dual specific Bcl-2\/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity. Eur J Cancer. 2014;50:109\u201310.","journal-title":"Eur J Cancer"},{"key":"4042_CR24","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1002\/cam4.3090","volume":"9","author":"H Yi","year":"2020","unstructured":"Yi H, Qiu M-Z, Yuan L, Luo Q, Pan W, Zhou S, et al. Bcl-2\/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020;9:4197\u2013206.","journal-title":"Cancer Med"},{"key":"4042_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3892\/ijo.2017.4028","volume":"51","author":"J Wang","year":"2017","unstructured":"Wang J, Yang D, Luo Q, Qiu M, Zhang L, Li B, et al. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2\/Bcl-xl in HL-60 cells. Int J Oncol. 2017;51:563\u201372.","journal-title":"Int J Oncol"},{"key":"4042_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10555-008-9169-0","volume":"28","author":"M Yilmaz","year":"2009","unstructured":"Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15\u201333.","journal-title":"Cancer Metastasis Rev"},{"key":"4042_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/1541-7786.MCR-13-0650","volume":"12","author":"F Pareja","year":"2014","unstructured":"Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res: MCR. 2014;12:987\u20131001.","journal-title":"Mol Cancer Res: MCR"},{"key":"4042_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1747-1028-5-14","volume":"5","author":"A Jarnicki","year":"2010","unstructured":"Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer\u2014more than a \u201cgut\u201d feeling? Cell Div. 2010;5:14\u201314.","journal-title":"Cell Div"},{"key":"4042_CR29","first-page":"3351","volume":"62","author":"M Masuda","year":"2002","unstructured":"Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62:3351\u20135.","journal-title":"Cancer Res"},{"key":"4042_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380.","journal-title":"Lancet"},{"key":"4042_CR31","doi-asserted-by":"publisher","unstructured":"Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Phil. Trans. Roy. Soc. London Ser. B: Biol. Sci. 2017;372:20160270. https:\/\/doi.org\/10.1098\/rstb.2016.0270","DOI":"10.1098\/rstb.2016.0270"},{"key":"4042_CR32","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1002\/cncr.10995","volume":"95","author":"BB Ma","year":"2002","unstructured":"Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002;95:2516\u201323.","journal-title":"Cancer"},{"key":"4042_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00280-007-0441-8","volume":"61","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:33\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4042_CR34","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.2147\/OTT.S261570","volume":"13","author":"Y Gu","year":"2020","unstructured":"Gu Y, Zhang B, Gu G, Yang X, Qian Z. Metformin increases the chemosensitivity of pancreatic cancer cells to gemcitabine by reversing EMT through regulation DNA methylation of miR-663. OncoTargets Ther. 2020;13:10417\u201329.","journal-title":"OncoTargets Ther"},{"key":"4042_CR35","doi-asserted-by":"publisher","unstructured":"Ando T, Ichikawa J, Fujimaki T, Taniguchi N, Takayama Y, Haro H. Gemcitabine and rapamycin exhibit additive effect against osteosarcoma by targeting autophagy and apoptosis. Cancers. 2020;12:3097. https:\/\/doi.org\/10.3390\/cancers12113097","DOI":"10.3390\/cancers12113097"},{"key":"4042_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73659-z","volume":"10","author":"LH Tsai","year":"2020","unstructured":"Tsai LH, Hsu KW, Chiang CM, Yang HJ, Liu YH, Yang SF, et al. Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. Sci Rep. 2020;10:17817.","journal-title":"Sci Rep"},{"key":"4042_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071\u201380.","journal-title":"Cell Death Differ"},{"key":"4042_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.coph.2011.04.013","volume":"11","author":"BH Choi","year":"2011","unstructured":"Choi BH, Yoon HS. FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol. 2011;11:354\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"4042_CR39","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1158\/0008-5472.CAN-05-3757","volume":"66","author":"JV Alvarez","year":"2006","unstructured":"Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006;66:3162\u20138.","journal-title":"Cancer Res"},{"key":"4042_CR40","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474\u201388.","journal-title":"Oncogene"},{"key":"4042_CR41","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945\u201353.","journal-title":"Lancet"},{"key":"4042_CR42","doi-asserted-by":"publisher","first-page":"9787","DOI":"10.1002\/jcb.28259","volume":"120","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kim C, Ko JH, Jung YY, Jung SH, Kim E, et al. Casticin inhibits growth and enhances ionizing radiation-induced apoptosis through the suppression of STAT3 signaling cascade. J Cell Biochem. 2019;120:9787\u201398.","journal-title":"J Cell Biochem"},{"key":"4042_CR43","doi-asserted-by":"publisher","unstructured":"Lee JH, Kim C, Lee SG, Sethi G, Ahn KS. Ophiopogonin D, a steroidal glycoside abrogates STAT3 signaling cascade and exhibits anti-cancer activity by causing GSH\/GSSG imbalance in lung carcinoma. Cancers. 2018;10:427. https:\/\/doi.org\/10.3390\/cancers10110427","DOI":"10.3390\/cancers10110427"},{"key":"4042_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","volume":"26","author":"ALA Wong","year":"2017","unstructured":"Wong ALA, Hirpara JL, Pervaiz S, Eu JQ, Sethi G, Goh BC. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investigational Drugs. 2017;26:883\u20137.","journal-title":"Expert Opin Investigational Drugs"},{"key":"4042_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1517\/14728222.8.5.409","volume":"8","author":"J Turkson","year":"2004","unstructured":"Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Therapeutic Targets. 2004;8:409\u201322.","journal-title":"Expert Opin Therapeutic Targets"},{"key":"4042_CR46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-021-00563-x","volume":"6","author":"W Dai","year":"2021","unstructured":"Dai W, Liu S, Wang S, Zhao L, Yang X, Zhou J, et al. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma. Signal Transduct Target Ther. 2021;6:176.","journal-title":"Signal Transduct Target Ther"},{"key":"4042_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.7150\/jca.35453","volume":"11","author":"M Zhou","year":"2020","unstructured":"Zhou M, Zhao J, Zhang Q, Jin X, Liao M, Zhang L, et al. Nicotine upregulates the level of Mcl-1 through STAT3 in H1299 Cells. J Cancer. 2020;11:1270\u20136.","journal-title":"J Cancer"},{"key":"4042_CR48","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1002\/jcp.26786","volume":"233","author":"A De Blasio","year":"2018","unstructured":"De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol. 2018;233:8482\u201398.","journal-title":"J Cell Physiol"},{"key":"4042_CR49","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1517\/13543784.2011.609167","volume":"20","author":"BA Quinn","year":"2011","unstructured":"Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investigational Drugs. 2011;20:1397\u2013411.","journal-title":"Expert Opin Investigational Drugs"},{"key":"4042_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01495-2","volume":"20","author":"IH Yang","year":"2020","unstructured":"Yang IH, Hong SH, Jung M, Ahn CH, Yoon HJ, Hong SD, et al. Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3-Mcl-1 signaling. Cancer Cell Int. 2020;20:405.","journal-title":"Cancer Cell Int"},{"key":"4042_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","volume":"80","author":"E Yang","year":"1995","unstructured":"Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285\u201391.","journal-title":"Cell"},{"key":"4042_CR52","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ceb.2003.10.004","volume":"15","author":"T Kuwana","year":"2003","unstructured":"Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003;15:691\u20139.","journal-title":"Curr Opin Cell Biol"},{"key":"4042_CR53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.cdd.4400519","volume":"6","author":"SP Holmgreen","year":"1999","unstructured":"Holmgreen SP, Huang DC, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death Differ. 1999;6:525\u201332.","journal-title":"Cell Death Differ"},{"key":"4042_CR54","first-page":"613","volume":"23","author":"YQ Zheng","year":"2019","unstructured":"Zheng YQ, Cui YR, Yang S, Wang YP, Qiu YJ, Hu WL. Opa interacting protein 5 promotes metastasis of nasopharyngeal carcinoma cells by promoting EMT via modulation of JAK2\/STAT3 signal. Eur Rev Med Pharmacol Sci. 2019;23:613\u201321.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4042_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2019.04.019","volume":"455","author":"M Luo","year":"2019","unstructured":"Luo M, Wu C, Guo E, Peng S, Zhang L, Sun W, et al. FOXO3a knockdown promotes radioresistance in nasopharyngeal carcinoma by inducing epithelial-mesenchymal transition and the Wnt\/\u03b2-catenin signaling pathway. Cancer Lett. 2019;455:26\u201335.","journal-title":"Cancer Lett"},{"key":"4042_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.05.018","volume":"337","author":"T Yoshizaki","year":"2013","unstructured":"Yoshizaki T, Kondo S, Wakisaka N, Murono S, Endo K, Sugimoto H, et al. Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma. Cancer Lett. 2013;337:1\u20137.","journal-title":"Cancer Lett"},{"key":"4042_CR57","doi-asserted-by":"publisher","first-page":"11793","DOI":"10.2147\/OTT.S235948","volume":"12","author":"Z Yang","year":"2019","unstructured":"Yang Z, Wang J, Zhang Z, Tang F. Epstein-Barr virus-encoded products promote circulating tumor cell generation: a novel mechanism of nasopharyngeal carcinoma metastasis. OncoTargets Ther. 2019;12:11793\u2013804.","journal-title":"OncoTargets Ther"},{"key":"4042_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","volume":"5","author":"X Guan","year":"2015","unstructured":"Guan X. Cancer metastases: challenges and opportunities. Acta Pharmaceutica Sin B. 2015;5:402\u201318.","journal-title":"Acta Pharmaceutica Sin B"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04042-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:15:22Z","timestamp":1669972522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04042-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Da-Jun Yang has ownership interest (including patents) in Ascentage Pharma Group Corp. Limited. Wen-Tao Pan is an employee of Ascentage Pharma Group Corp. Limited. No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Guangdong Provincial Animal Care and Use Committee approved all the in vivo experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"772"}}